Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Ag Ord (OP:BAYZF)

31.79 +1.43 (+4.69%)
Streaming Delayed Price Updated: 3:38 PM EDT, Jun 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag Ord

< Previous 1 2 3 Next >
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
Exposures Product Safety
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities
Via Benzinga
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Via Benzinga
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm
Via Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Reuters 
Via Benzinga
Activist Investor Builds Stake In Bayer, Pushes Breakup
Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.  
Via Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
Via Benzinga
Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor
Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup... 
Via Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Reuters Rebranded McDonald’s Restaurants To Reopen In Russia 
Via Benzinga
US Top Court To Decide On Bayer's Roundup Weedkiller Appeal
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY). The expanded... 
Via Benzinga
Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial
Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical... 
Via Benzinga
Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities
Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries... 
Via Benzinga
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related... 
Via Benzinga
Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates
Berkeley Lights Inc (NASDAQ: BLI) reports Q2 sales of $19.3 million, +82% Y/Y, but slightly missing the consensus of $19.64 million. The Company expanded the installed... 
Via Benzinga
Topics Earnings
Exposures Financial
Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod
The European Commission (EC) has approved Merck & Co Inc's (NYSE: MRK) soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). Verquvo... 
Via Benzinga
Bayer's Kerendia Scores Long-Awaited Kidney & Heart Disease Nod For Type 2 Diabetes
The FDA on Friday approved Bayer AG's (OTC: BAYRY) chronic kidney disease (CKD) drug Kerendia (finerenone), the first and only nonsteroidal mineralocorticoid... 
Via Benzinga
Exposures Product Safety
Why Did Novocure Shares Plunge Today?
Novocure Ltd (NASDAQ: NVCR) has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields (TTFields) together with Bayer... 
Via Benzinga
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials
Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.